Low-Dose Ketamine Case Studies: Clinical Outcomes and Lessons

Low-dose ketamine case studies clinical outcomes and lessons are most useful when read as clinical illustrations, not proof that a treatment will work for any one person. Published trials support rapid symptom improvement for some carefully selected patients with treatment-resistant depression, PTSD, suicidal thoughts, and certain pain conditions, but dosing, monitoring, maintenance needs, and results vary widely.

The five anonymized composite cases below reflect common scenarios described in published literature. They are not individual patient records, and they cannot establish causation. Their practical value is in showing the questions clinicians may consider: what symptoms are being measured, how safety is monitored, whether concurrent medicines may matter, and when another treatment should be added.

What the published evidence can and cannot show

Randomized trials provide stronger evidence than case reports or composite examples. In a two-site randomized trial of adults with treatment-resistant major depression, researchers reported that 64% of participants receiving a single 0.5 mg/kg intravenous ketamine infusion met response criteria at 24 hours, compared with 28% receiving midazolam. The study measured a short-term result, so it does not establish the best maintenance plan for every patient. Read the Murrough et al. trial abstract.

Ketamine is not interchangeable with every ketamine-related treatment. The U.S. Food and Drug Administration has approved esketamine nasal spray for specific depressive-disorder indications under a Risk Evaluation and Mitigation Strategy, while many intravenous, oral, and sublingual ketamine uses are evaluated differently in clinical practice. Readers considering treatment should understand the proposed route, monitoring plan, and evidence for their condition. See the FDA announcement on esketamine.

Five clinical scenarios and their practical lessons

1. Treatment-resistant depression with partial antidepressant benefit

A middle-aged patient with persistent depression despite several medication trials continued duloxetine while receiving six intravenous infusions at 0.5 mg/kg over 40 minutes. Her PHQ-9 and MADRS scores improved during induction, then worsened when a maintenance infusion was delayed. The lesson is not that every patient needs an identical schedule. It is that symptom scales and follow-up can help clinicians distinguish a temporary response from a pattern that may require maintenance planning. See how many ketamine treatments may be needed for a discussion of induction and follow-up questions.

2. PTSD with chronic pain

A veteran with PTSD and chronic back pain reported improvements in hypervigilance, sleep, and pain after an intravenous induction series, then resumed trauma-focused psychotherapy during maintenance. An early randomized trial found symptom improvement with intravenous ketamine in chronic PTSD, though PTSD care still requires a broader assessment and evidence-based psychotherapy when appropriate. Read the Feder et al. PTSD trial abstract. The useful clinical question is whether symptom relief helps a patient participate in other care, not whether ketamine replaces that care.

3. Complex regional pain syndrome

A patient with long-standing CRPS received longer, more intensive monitored infusions than the depression examples and reported less pain and allodynia, followed by periodic boosters. Pain protocols described in the literature can differ substantially from psychiatric protocols in dose, duration, setting, and monitoring. The CRPS study by Sigtermans and colleagues is a key source for this distinction. Read the CRPS study abstract.

4. Bipolar depression with benzodiazepine use

A patient maintained on lamotrigine gradually reduced, but did not abruptly stop, clonazepam before ketamine treatment. He had a partial response that required close mood monitoring and continued use of a mood stabilizer. Benzodiazepines may affect antidepressant response in some reports, but medication changes must account for withdrawal risk, anxiety, and the prescriber's judgment. Read more about ketamine and benzodiazepines.

5. Acute suicidal ideation

A young adult received closely observed infusions while medication treatment and dialectical behavior therapy were being established. Her suicidal thoughts eased quickly in the composite scenario, then ketamine was tapered after other supports were in place. Rapid symptom change should never replace emergency assessment, supervision, or a safety plan when someone has active suicidal thoughts, a plan, or immediate danger. The National Institute of Mental Health describes rapid-acting treatments as an active area of depression research. See NIMH information on depression treatment.

Clinical themes readers can use

Response timing differs. Some people report change after one or several treatments, while others have little benefit. A clinician should assess the trend with the same measures over time instead of relying only on a single good or bad day.

Maintenance is a decision, not an assumption. Several composites required continued administration, while the acute-suicidality example used ketamine as a temporary bridge while other treatment was strengthened. Questions about treatment spacing should be answered in the context of response, adverse effects, practical access, and the underlying condition.

Safety monitoring remains central. Transient blood-pressure increases, dissociation, nausea, and sedation can occur with ketamine treatment. The appropriate setting and observation plan depend on the route, dose, medical history, psychiatric history, and local clinical protocol. See cardiovascular monitoring during ketamine treatment for related considerations.